← Back to headlines
Pfizer Strikes Cancer Therapy Deal with China's Innovent Biologics
Pfizer has entered into a deal worth up to $10.5 billion with China's Innovent Biologics to develop next-generation cancer therapies, marking a significant collaboration in the pharmaceutical sector.
30 May, 22:01 — 30 May, 22:01
Sources
Showing 1 of 1 sources
